Retatrutide's GLP, GIP, GLUCAGON Edge (vs. Ozempic's Single Hit) 💣

Hey brother,

Ozempic tiptoed.

Wegovy jogged.

Retatrutide?

It hits a different target altogether. 🎯 

This triple-agonist sledgehammer hits THREE receptors at once: [5]

✅ GLP-1

✅ GIP

✅ Glucagon

...and vaporizes 24.2% of your body weight in 48 weeks. [2]

Not 14% like Ozempic.

Not 20% like Wegovy.

Twenty. Four. Percent.

Meet Tom, 48, Former Army Ranger...

He'd tried everything.

Ozempic plateaued him at 14%.

Wegovy got him to 18%... then stalled.

But when he joined the Phase 2 retatrutide trial?

His wife didn't recognize him at the airport... 🛬

"I thought you were sending your younger brother to pick me up!"

48 weeks. 72 pounds gone. From 295 to 223.

And here's what really blew the researchers' minds...

The Fat-to-Muscle Flip That Changes Everything

Listen to this:

Here's what separates Retatrutide from Ozempic and Wegovy:

While semaglutide and tirzepatide rely primarily on appetite suppression...

Retatrutide's glucagon component...

forces active fat burning...

while preserving lean mass.

The data: In the Coskun Phase 2 substudy...

participants lost 33.7% of baseline fat mass while retaining 97% of lean muscle. [2][3][9]

That's the difference between getting smaller and getting better.

It acts like a metabolic furnace.

The body composition analysis shows: [3]

• Fat mass: OBLITERATED (-33.7% reduction)

• Lean muscle: PRESERVED (minimal loss)

• Visceral fat: GUTTED (the dangerous belly fat around your organs)

You're not just getting smaller...

You're getting BETTER.

Type 2 diabetics saw their bodies literally transform... [3][10]

More muscle definition...

Less jiggly regret...

A metabolic reset that turns you into a fat-burning furnace.

The Triple-Threat Mechanism

Here's why retatrutide makes other drugs look like water pistols:

Receptor #1: GLP-1 (like Ozempic/Wegovy) Makes you feel full... slows stomach emptying... reduces cravings [7]

Receptor #2: GIP (like Mounjaro adds) Supercharges insulin response... optimizes nutrient partitioning [9]

Receptor #3: GLUCAGON (the game-changer) Cranks up energy expenditure... forces fat burning... preserves muscle [11]

It's like having three Navy SEALs attacking your fat stores from different angles... 🎯

While Ozempic brings a knife to the fight...

And Wegovy brings a handgun...

Retatrutide shows up with a tactical nuke.

Beyond Weight Loss: The Total Body Overhaul [6]

But weight loss is just the beginning...

The TRIUMPH trials are testing retatrutide for:

Sleep Apnea: Early data suggests it could cure your snoring AND your CPAP dependency [1]

Knee Osteoarthritis: Less weight = less pain = getting back to morning runs [1]

Cardiovascular Protection: Following Wegovy's footsteps with likely 20%+ reduction in heart attacks/strokes [8]

Meta-Analysis Screams Safety

Before you ask "but is it safe?"...

A 2025 meta-analysis of all retatrutide trials shows: [4]

✓ Well-tolerated across all doses

✓ Side effects like other GLP-1s (mostly mild GI)

✓ No major safety signals

✓ Drop-out rates comparable to Wegovy

The most common side effect?

Needing to buy new clothes... 👔 😂

Real-World Response by Dose

Here's what the Phase 2 heroes achieved: [2]

At 4mg weekly: -17.8% body weight

At 8mg weekly: -22.8% body weight

At 12mg weekly: -24.2% body weight

And get this...

The weight loss hadn't plateaued yet when the trial ended!

Researchers believe 30%+ is possible with longer treatment...

Your Move, Man.

The future isn't coming.

It's here.

While your buddies struggle with their Ozempic plateaus...

You could be melting fat at unprecedented rates.

Retatrutide isn't FDA approved yet...

But Phase 3 TRIUMPH trials are enrolling NOW. [1]

What's it gonna be?

Ready to see if you qualify for TRIUMPH?

Reply NEW ME...

and the 1-page PDF quick-start on Retatrutide is yours.

I'll send the enrollment criteria, the dosing protocol, and exactly what to ask your doctor.

Don't watch the revolution from the sidelines.

Lead it.

To your transformation,

Mens Health Secrets 
–Live Past 100

P.S. Next email reveals CagriSema's amylin magic... Imagine Wegovy's power DOUBLED with hunger control so strong, you'll forget food exists. One trial participant said: "It's like someone turned off my appetite switch completely." Coming next... 🔥

P.P.S. Always consult your physician before starting any weight-loss medication. This is for education and entertainment only. We assume no liability.

P.P.P.S. >>> Go here to subscribe to our Mens Health Secrets YouTube Channel if you haven't yet…. leave a comment… and level up your Mens Health knowledge to live longer.

P.P.P.P.S. New Skool group: Free for life through Q2. Reply "TRIBE." Your community is ready.

Medical References:

Retatrutide – Triple agonist (emerging)

[1] Giblin, K., Bethel, M. A., Lalonde, A., Ahmad, N., Wu, Q., & Kaplan, L. M. (2026). Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism, 28(1), 83-93. https://doi.org/10.1111/dom.70209 (TRIUMPH design: Phase 3 for multi-comorbidities.)

[2] Jastreboff, A. M., Kaplan, L. M., & Hartman, M. L. (2023). Triple-hormone-receptor agonist retatrutide for obesity - A phase 2 trial. New England Journal of Medicine, 389(6), 514-526. https://doi.org/10.1056/NEJMoa2301972 (Phase 2: Up to 24% loss at 48 weeks.)

[3] Coskun, T., Nunez, D. J., Somers, K. J., ... & Hartman, M. L. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: A substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology, 13(8), 674-684. https://doi.org/10.1016/S2213-8587(25)00092-0 (Substudy: Significant fat mass reduction vs. placebo.)

[4] Abouelmagd, A. A., El-Gendy, A. O., & El-Sayed, M. A. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: A systematic review and meta-analysis of randomized controlled trials. Proceedings (Baylor University. Medical Center), 38(3), 291-303. https://doi.org/10.1080/08998280.2025.2456441 (Meta: ~22% average loss; good safety.)

[5] Kaur, M., Kumar, A., & Singh, A. (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European Journal of Clinical Pharmacology, 80(5), 669-676. https://doi.org/10.1007/s00228-024-03646-0 (Review: Phase 2 showed 17-24% loss.)

[6] Sanyal, A. J., Kaplan, L. M., Frias, J. P., et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30(7), 2037–2048. https://doi.org/10.1038/s41591-024-03018-2 

[7] Sinha, B., & Ghosal, S. (2025). Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity (Silver Spring), 33(11), 2046-2054. https://doi.org/10.1002/oby.24360

[8] Chou, O. H. I., Zhou, H., Waraich, H., et al. (2025). Differential effects of glucagon-like peptide-1 receptor agonist classes on blood pressure: a systematic review and network meta-analysis of randomised controlled trials. medRxiv. https://doi.org/10.1101/2025.07.05.25330933

[9] Coskun, T., Urva, S., Roell, W. C., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013

[10] Urva, S., Coskun, T., Loh, M. T., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet, 400(10366), 1869–1881.https://doi.org/10.1016/S0140-6736(22)02033-5

[11] Salem V, Izzi-Engbeaya C, Coello C, Thomas DB, Chambers ES, Comninos AN, Buckley A, Win Z, Al-Nahhas A, Rabiner EA, Gunn RN, Budge H, Symonds ME, Bloom SR, Tan TM, Dhillo WS. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2016 Jan;18(1):72-81. https://doi.org/10.1111/dom.12585. Epub 2015 Nov 20. PMID: 26434748; PMCID: PMC4710848.